PRMT5 inhibitors

US12173026B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• MSD INTERNATIONAL GMBH · CH

Inventors

• Michelle R. Machacek · Brookline, US
• David J. Witter · Norfolk, US
• Craig R. Gibeau · Holliston, US
• Chunhui Huang · Arlington, US
• Shuhei Kawamura · Cambridge, US
• David L. Sloman · Brookline, US
• Phieng Siliphaivanh · Newton, US
• Ryan Quiroz · Boston, US
• Murray Wan · Watertown, US
• Sebastian Schneider · Boston, US
• Charles S. Yeung · Dedham, US
• Michael H. Reutershan · Watertown, US
• Timothy J. Henderson · Natick, US
• Jean-Laurent Paparin · Vendémian, FR
• Houcine Rahali · Villeneuve-lès-Avignon, FR
• Jonathan M. E. Hughes · Hoboken, US
• Sulagna Sanyal · Belmont, US
• Yingchun Ye · Belmont, US
• David A. Candito · Wrentham, US
• Patrick Fier · Berkeley, US
• Steven M. Silverman · Jersey City, US

Key dates

• Filing date: Aug 5, 2019
• Grant date: Dec 24, 2024
• Expiry date: Oct 27, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.